Q1 Earnings Estimate for Biodesix Issued By William Blair

Biodesix, Inc. (NASDAQ:BDSX - Free Report) - Stock analysts at William Blair issued their Q1 2025 EPS estimates for shares of Biodesix in a note issued to investors on Tuesday, March 4th. William Blair analyst A. Brackmann expects that the company will post earnings of ($0.08) per share for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Biodesix's current full-year earnings is ($0.35) per share. William Blair also issued estimates for Biodesix's Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.22) EPS.

Biodesix (NASDAQ:BDSX - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The firm had revenue of $20.43 million for the quarter, compared to analyst estimates of $19.92 million.

Biodesix Stock Up 1.4 %

BDSX stock traded up $0.01 during trading on Thursday, reaching $0.86. The stock had a trading volume of 348,600 shares, compared to its average volume of 510,352. Biodesix has a 1-year low of $0.64 and a 1-year high of $2.04. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. The company has a market capitalization of $125.42 million, a P/E ratio of -2.21 and a beta of 1.10. The firm has a fifty day moving average price of $1.07 and a 200 day moving average price of $1.40.

Remove Ads

Institutional Investors Weigh In On Biodesix

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in shares of Biodesix by 50.7% in the 3rd quarter. Geode Capital Management LLC now owns 804,576 shares of the company's stock worth $1,433,000 after purchasing an additional 270,724 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Biodesix in the 3rd quarter worth about $10,849,000. Barclays PLC increased its position in shares of Biodesix by 1,140.5% in the 3rd quarter. Barclays PLC now owns 23,036 shares of the company's stock worth $41,000 after purchasing an additional 21,179 shares during the last quarter. Stephens Inc. AR bought a new stake in shares of Biodesix in the 4th quarter worth about $303,000. Finally, Perkins Capital Management Inc. increased its position in shares of Biodesix by 74.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company's stock worth $1,290,000 after purchasing an additional 310,000 shares during the last quarter. Institutional investors own 20.96% of the company's stock.

Insiders Place Their Bets

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of the business's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $76,967.20. Following the transaction, the chief executive officer now owns 701,947 shares in the company, valued at $645,791.24. The trade was a 10.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 128,702 shares of company stock worth $118,406 in the last quarter. 69.20% of the stock is owned by corporate insiders.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.